A study to test the safety and tolerability of Lu AH69593 in adults that are healthy or have narcolepsy.

2024-511073-29-00 Protocol 20653A Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 13 Jun 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol 20653A

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 104
Countries 1
Sites 2

Narcolepsy

Key facts

Sponsor
H. Lundbeck A/S
Participant type
Healthy volunteers, Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
13 Jun 2025 → ongoing
Decision date (initial)
2025-05-27
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Narcolepsy

VersionLevelCodeTermSystem organ class
20.0 LLT 10007738 Cataplexy and narcolepsy 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

H. Lundbeck A/S

Sponsor organisation
H. Lundbeck A/S
Address
Ottiliavej 9
City
Valby
Postcode
2500
Country
Denmark

Scientific contact point

Organisation
H. Lundbeck A/S
Contact name
Clinical Trial Information

Public contact point

Organisation
H. Lundbeck A/S
Contact name
Clinical Trial Information

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Finland Ongoing, recruiting 104 2
Rest of world 0

Investigational sites

Finland

2 sites · Ongoing, recruiting
Suomen Terveystalo Oy
Terveystalo Sleep Clinic, Valimotie 21, 00380, Helsinki
Clinical Research Services Turku CRST Oy
CRST Turku, Joukahaisenkatu 2 B, 20520, Turku

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Finland 2025-06-13 2025-06-13

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-13 Finland Acceptable
2025-05-26
2025-05-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-05-28 Finland Acceptable 2025-06-13
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-12 Finland Acceptable
2026-02-19
2026-02-19
4 SUBSTANTIAL MODIFICATION SM-3 2026-04-20 Finland Acceptable
2026-05-18
2026-05-19